Annika Möhl

Annika Möhl

Auto-generated profile, based on publicly available information

Annika Möhl

Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf , Hamburg

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Cancer
Verified
Journal Article
Open access
PDF file
AMAnnika Möhl
Annika Möhl
EOEster Orban
Ester Orban
AJAudrey Y. Jung
Audrey Y. Jung
SBSabine Behrens
Sabine Behrens
NONadia Obi
Nadia Obi
Heiko BecherHeiko Becher
Heiko Becher
Background: The number of elderly cancer survivors is growing because of increasing survival rates. A high comorbidity burden in the elderly can affect their quality of life and survival. The aim of this study was to examine whether breast cancer survivors and population‐based controls have a different comorbidity burden after long‐term follow‐up.Methods: This study used data from a German breast cancer case‐control study, which initially comprised 3813 breast cancer cases aged 50 to 74 years who were diagnosed between 2002 and 2005 and 7341 population‐based controls. Participants were followed up in 2014/2016. A modified Charlson Comorbidity Index (mCCI) was calculated to quantify severe comorbidities. Negative binomial regression was performed to estimate rate ratios (RRs) with 95% confidence intervals (CIs) for the association between case‐control status and mCCI (dependent variable) for the baseline population and for those who participated at follow‐up, with adjustments made for relevant lifestyle factors.Results: In total, 1925 cases and 3674 controls participated in the follow‐up 12 years after recruitment. In the baseline population 35% had at least 1 comorbid condition.In long‐term survivors this proportion was 52%. No difference was found in the mCCI between breast cancer cases and controls at baseline (RR, 1.05; 95% CI, 0.98‐1.11) or between long‐term survivors of the 2 groups at baseline (RR, 1.07; 95% CI, 0.97‐1.18) or at follow‐up (RR, 1.00; 95% CI, 0.91‐1.10).Conclusions: The comorbidity burden of long‐term breast cancer survivors and controls increased over time; however, it remained similar in both groups after 12 years of follow‐up.

27 July 2023 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
AMAnnika Möhl
Annika Möhl
SBSabine Behrens
Sabine Behrens
FFFabian Flaßkamp
Fabian Flaßkamp
NONadia Obi
Nadia Obi
AKAnnika Kreienbrinck
Annika Kreienbrinck
HBHeiko Becher
Heiko Becher
Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. The aim of this study was to examine if CVD affects the mortality of women after a breast cancer diagnosis and population controls differently. Methods: The analysis included a total of 3,555 women, diagnosed with primary stage 1–3 breast cancer or in situ carcinoma between 2002 and 2005 and 7,334 controls breast cancer-free at recruitment, all aged 50–74 years, who were followed-up in a German breast cancer case–control study until June, 30 2020. Kaplan–Meier and cumulative incidence function were calculated for all-cause mortality and mortality from any cancer, stratified for case–control status and CVD, separately for women aged < 65 and ≥ 65 years. Cox regression and Fine-Gray subdistribution hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between case–control-status, CVD and mortality from all causes/any cancer. Results: The median follow-up was 16.1 years. In total, 1,172 cases (33.0%) and 1,401 initial controls (19.1%) died. CVD prevalence at recruitment was 15.2% in cases and controls. Cases with CVD had the highest and controls without CVD the lowest mortality during the entire observation period in both age groups (< 65 and ≥ 65 years). CVD was identified as a risk factor for all-cause mortality in both cases and controls aged < 65 years (HR 1.22, 95%CI 0.96–1.55 and HR 1.79, 95%CI 1.43–2.24) as well as at ages of ≥ 65 years (HR 1.44, 95%CI 1.20–1.73 and HR 1.59, 95%CI 1.37–1.83). A significant association of CVD and cancer mortality was found only for cases aged ≥ 65 years. Conclusion: CVD was significantly associated with all-cause mortality of both cases and controls and CVD was identified as a risk factor for cancer mortality of cases aged ≥ 65 years at recruitment. Therefore, attention should be paid on monitoring and preventing CVD in breast cancer patients, especially in those diagnosed at older ages.

28 April 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
OFOdette Fründt
Odette Fründt
AHAnne-Marie Hanff
Anne-Marie Hanff
AMAnnika Möhl
Annika Möhl
TMTobias Mai
Tobias Mai
CKChristiane Kirchner
Christiane Kirchner
MSMartin Südmeyer
Martin Südmeyer
Data on the use of device-aided therapies (DATs) in people with Parkinson’s disease (PwP) are scarce. Analyzing data from the Care4PD patient survey, we (1) evaluated application frequency and type of DAT in a larger, nationwide, cross-sectoral PwP sample in Germany; (2) analyzed the frequency of symptoms indicative for advanced PD (aPD) and need for DAT amongst the remaining patients and (3) compared the most bothersome symptoms and need for professional long-term care (LTC) of patients with and without suspected aPD. Data from 1269 PwP were analyzed. In total, 153 PwP (12%) received DAT, mainly deep brain stimulation (DBS). Of the remaining 1116 PwP without DAT, >50% fulfilled at least one aPD criterion. Akinesia/rigidity and autonomic problems were most bothersome for PwP with and without suspected aPD, with more tremor in the non-aPD and more motor fluctuations and falls in the aPD group. To recapitulate, the German DAT application rate is rather low, although a large proportion of PwP fulfills aPD criteria indicating a need for intensified treatment strategies. Many reported bothersome symptoms could be overcome with DAT with benefits even for LTC patients. Thus, precise and early identification of aPD symptoms (and therapy-resistant tremor) should be implemented in future DAT preselection tools and educational trainings.

20 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
PVPatrizio Vanella
Patrizio Vanella
CWChristian Wiessner
Christian Wiessner
AHAnja Holz
Anja Holz
GKGérard Krause
Gérard Krause
AMAnnika Moehl
Annika Moehl
Heiko BecherHeiko Becher
Heiko Becher
European countries report large differences in COVID-19 case fatality risk (CFR) and high variation over the year. CFR estimates may both depend on the method used for estimation and of country-specific characteristics. While crude methods simply use cumulative total numbers of cases and deaths, the CFR can be influenced by the demographic characteristics of the cases, case detection rates, time lags between reporting of infections and deaths and infrastructural characteristics, such as healthcare capacities. We used publicly available weekly data from the national health authorities of Germany, Italy, France and Spain on case and death numbers by age group connected to COVID-19 for the year 2020. We propose to use smoothed data of national weekly test rates for case adjustment and investigated the impact of different time lags from case reporting to death on the estimation of the CFR. Finally, we described the association between case fatality and the demand for hospital beds for COVID-19, taking into account national hospital bed capacities. Crude CFR estimates differ considerably between the four study countries with end-of-year values of approximately 1.9%, 3.5%, 2.5% and 2.7% for Germany, Italy, France and Spain, respectively. Age-adjustment reduces the differences considerably, resulting in values of 1.61%, 2.4% and 2% for Germany, Italy and Spain, respectively. France’s age-specific data was restricted to hospitalised cases only and is therefore not comparable in that regard. International crude International CFR time series show smaller differences when adjusting for demographics of the cases or the test rates. Curves adjusted for age structure, testing or time lags show smaller variance over the year and a smaller degree of non-stationarity. The data does not suggest any connection of CFRs to hospital capacities for the four countries under study.

11 November 2023 in Cancer
Verified
Journal Article
Open access
Kathleen GaliKathleen Gali
Kathleen Gali
EOEster Orban
Ester Orban
AOAnn‐Kathrin Ozga
Ann‐Kathrin Ozga
AMAnnika Möhl
Annika Möhl
SBSabine Behrens
Sabine Behrens
JCJenny Chang‐Claude
Jenny Chang‐Claude
BackgroundModifiable lifestyle factors are known to impact survival. It is less clear whether this differs between postmenopausal women ever diagnosed with breast cancer and unaffected women.MethodsWomen diagnosed with breast cancer and unaffected women of comparable age were recruited from 2002 to 2005 and followed up until 2020. Using baseline information, a lifestyle adherence score (range 0-8; categorized as low [0-3.74], moderate [3.75-4.74], and high [>= 4.75]) was created based on the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. Cox regression and competing risks analysis were used to analyze the association of adherence to WCRF/AICR lifestyle recommendations with overall mortality and with death due to cardiovascular diseases and cancer, respectively.ResultsA total of 8584 women were included (2785 with breast cancer and 5799 without). With a median follow-up of 16.1 years there were 2006 total deaths. Among the deaths of known causes (98.6%), 445 were cardiovascular-related and 1004 were cancer-related. The average lifestyle score was 4.2. There was no differential effect of lifestyle score by case-control status on mortality. After adjusting for covariates, moderate (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.57-0.76) and high (HR, 0.54; 95% CI, 0.47-0.63) adherence to WCRF/AICR lifestyle recommendations were significantly associated with a decrease in overall mortality. Similarly, in competing risks analysis, moderate and high adherence were associated with decreased mortality from cardiovascular diseases and from cancer.ConclusionsA healthy lifestyle can substantially reduce mortality risk in women. With low adherence to all WCRF/AICR guidelines in about a third of study participants, health interventions are warranted. There was no differential effect of a breast cancer diagnosis on the association between healthy lifestyle score and lower mortality in postmenopausal women.

24 June 2024 in American Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
KMKevin Maldonado-Cañón
Kevin Maldonado-Cañón
AMAnnika Möhl
Annika Möhl
NONadia Obi
Nadia Obi
SBSabine Behrens
Sabine Behrens
FFFabian Flaßkamp
Fabian Flaßkamp
Heiko BecherHeiko Becher
Heiko Becher
Agreement to participate in case–control studies has become low. Healthy participant bias resulting from differential response proportions in cases and controls can distort results; however, the magnitude of bias is difficult to assess. We investigated the effect in a large population-based case–control study on breast cancer, with a participation rate of 43.4% and 64.1% for controls and cases, respectively. We performed a mortality follow-up in 2020 for 3813 cases and 7335 controls recruited during 2002-2005. Standardized mortality ratios (SMRs) for overall mortality and selected causes of death were estimated. The mean age at recruitment was 63.1 years. The overall mortality for controls was 0.66 times lower (95% CI, 0.62–0.69) than for the reference population. For causes of death other than breast cancer, SMRs were similar in cases and controls (0.70 and 0.64). Higher education was associated with lower SMRs in both cases and controls. Options for adjusting the healthy participant bias are limited if the true risk factor distribution in the underlying population is unknown. However, a relevant bias in this particular case–control study is considered unlikely since a similar healthy participant effect was observed for both controls and cases.